AHARON SCHWARTZ, PH.D. - Corporate Board Profile

Protalix BioTherapeutics, Inc.

Filing Date	Source Excerpt
2014-10-09	Aharon Schwartz, Ph.D. has retired from Teva Pharmaceutical Industries in 2011 where he served in a number of positions from 1975 through 2011, the most recent being Vice President, Head of Teva Innovative Ventures from 2008. ... Dr. Schwartz is currently chairman of the board of directors of a number of life science companies. ... He received his Ph.D. in organic chemistry in 1978 from the Weizmann Institute, his M.Sc. in organic chemistry from the Technion and a B.Sc. in chemistry and physics from the Hebrew University of Jerusalem. ... We believe Dr. Schwartz's qualifications to serve on our Board of Directors include his extensive experience in the life science industry.
2015-10-01	Aharon Schwartz was elected to serve on our Board of Directors on November 10, 2014. ... Compensation of Directors table shows Aharon Schwartz fees earned or paid in cash $5,555, no option awards, total $5,555.
2016-07-01	Aharon Schwartz, Ph.D. retired from Teva in 2011. ... Compensation of Directors table: Aharon Schwartz Fees Earned or Paid in Cash ($) 40,000 Option Award(s) ($) 0 Total ($) 40,000.
2017-03-16	Aharon Schwartz, Ph.D. has served as our director since November 2014. ... Compensation of Directors table shows Aharon Schwartz, Ph.D. fees earned or paid in cash $40,000, total $40,000.
2017-08-25	The following table sets forth information, as of August 10, 2017, regarding beneficial ownership of our common stock: Name and Address of Beneficial Owner Amount and Nature of Beneficial Ownership Percentage of Class (%) Board of Directors and Executive Officers Aharon Schwartz, Ph.D.
2017-09-01	Board of Directors and Executive Officers Aharon Schwartz, Ph.D.
2018-03-06	Aharon Schwartz, Ph.D. Dr. Schwartz has served as our director since November 2014. ... Dr. Schwartz has been appointed by our Board of Directors to replace Ms. Harel Buchris on the Audit Committee as of the meeting date. ... Dr. Schwartz has been appointed by our Board of Directors to replace Ms. Harel Buchris on the Compensation Committee as of the meeting date. ... Dr. Schwartz has been appointed by our Board of Directors to replace Ms. Harel Buchris on the Nominating Committee as of the meeting date. ... The following table sets forth information with respect to compensation of our non-employee directors during fiscal year 2017. ... Aharon Schwartz, Ph.D. Fees Earned or Paid in Cash ($) 40,000 Total ($) 40,000.
2018-10-17	Aharon Schwartz, Ph.D.
2019-04-12	Aharon Schwartz, Ph.D. Dr. Schwartz has served as our director since November 2014. ... Under these standards, our Board of Directors has determined that Dr. Schwartz is considered “independent” pursuant to the rules of the NYSE American. ... Our Board of Directors has an Audit Committee, Compensation Committee and Nominating Committee. The following indicates the members of each committee: ... The Audit Committee is currently comprised of ... Dr. Schwartz. ... The Compensation Committee is currently comprised of ... Dr. Schwartz. ... The Nominating Committee, currently comprised of ... Dr. Schwartz. ... The following table sets forth information with respect to compensation of our non-employee directors during fiscal year 2018. ... Aharon Schwartz, Ph.D. Fees Earned or Paid in Cash ($) 65,556 Total ($) 65,556.
2019-10-15	Security Ownership of Certain Beneficial Owners and Management table
2020-04-15	Aharon Schwartz, Ph.D. Dr. Schwartz has served as our director since November 2014. ... Our Board of Directors has an Audit and Finance Committee, Compensation Committee and Nominating Committee. The membership of each committee is as follows: ... Audit and Finance Committee David Granot, Amos Bar Shalev and Aharon Schwartz, Ph.D. ... Compensation Committee Amos Bar Shalev, David Granot and Aharon Schwartz, Ph.D. ... Nominating Committee Amos Bar Shalev, David Granot and Aharon Schwartz, Ph.D. ... The following table sets forth information with respect to compensation of our non-employee directors during fiscal year 2019. ... Aharon Schwartz, Ph.D. 80,000
2021-06-04	Aharon Schwartz, Ph.D. Dr. Schwartz has served as our director since November 2014. ... Committee memberships: Audit and Finance Committee, Compensation Committee, Nominating Committee. ... Fees Earned or Paid in Cash ($): 40,000, Option Award(s) ($): 54,591, Total ($): 94,591.
2021-09-30	Aharon Schwartz, Ph.D. Consists of 64,000 outstanding shares of our common stock and 17,500 shares of our common stock issuable upon exercise of outstanding options
2022-04-29	Aharon Schwartz, Ph.D. Dr. Schwartz has served as our director since November 2014. He retired from Teva in 2011 where he served in a number of positions from 1975 through 2011, the most recent being Vice President, Head of Teva Innovative Ventures from 2008. Dr. Schwartz is currently chairman of the Board of Directors of BiolineRx Ltd. (NASDAQ:BLRX, TASE:BLRX) and a member of the Board of Directors of Barcode Ltd. He also serves as the Head of the Advisory Board of Oncohost Ltd. and works as an independent consultant. From May 2015 through March 2020, he served as a member of the Board of Directors of Foamix Pharmaceuticals Ltd., (Nasdaq: FOMX) which was acquired by Menlo Therapeutics Inc. (Nasdaq: MNLO), and from January 2013 through November 2017, he served as a member of the Board of Directors of Alcobra Ltd., which is now called Arcturus Therapeutics Ltd. Dr. Schwartz received his Ph.D. in organic chemistry in 1978 from the Weizmann Institute of Science, his M.Sc. in organic chemistry from the Technion and a B.Sc. in chemistry and physics from the Hebrew University of Jerusalem. Dr. Schwartz received a second Ph.D. in 2014 from the Hebrew University of Jerusalem in the history and philosophy of science. We believe Dr. Schwartz’s qualifications to serve on our Board of Directors include his years of experience at life science companies.
2023-05-18	Aharon Schwartz, Ph.D. Dr. Schwartz has served as our director since November 2014. He retired from Teva in 2011 where he served in a number of positions from 1975 through 2011, the most recent being Vice President, Head of Teva Innovative Ventures from 2008. Dr. Schwartz is currently chairman of the Board of Directors of BiolineRx Ltd. (NASDAQ:BLRX, TASE:BLRX) and a member of the Board of Directors of Barcode Ltd. He also serves as the Head of the Advisory Board of Oncohost Ltd. and works as an independent consultant. From May 2015 through March 2020, he served as a member of the Board of Directors of Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), which was acquired by Menlo Therapeutics Inc. (Nasdaq: MNLO), and from January 2013 through November 2017, he served as a member of the Board of Directors of Alcobra Ltd., which is now called Arcturus Therapeutics Ltd. Dr. Schwartz received his Ph.D. in organic chemistry in 1978 from the Weizmann Institute of Science, his M.Sc. in organic chemistry from the Technion and a B.Sc. in chemistry and physics from the Hebrew University of Jerusalem. Dr. Schwartz received a second Ph.D. in 2014 from the Hebrew University of Jerusalem in the history and philosophy of science. We believe Dr. Schwartz’s qualifications to serve on our Board of Directors include his years of experience at life science companies.
2024-04-29	Aharon Schwartz, Ph.D. Dr. Schwartz joined our Board of Directors in November 2014. ... The Board of Directors has determined that ... Dr. Schwartz ... is an “independent director” ... The membership of each committee is as follows: Audit and Finance Committee Chairman: Shmuel “Muli” Ben Zvi, Ph.D.; Membership: Shmuel “Muli” Ben Zvi, Ph.D., Amos Bar Shalev and Aharon Schwartz, Ph.D. ... Compensation Committee Chairman: Amos Bar Shalev; Membership: Amos Bar Shalev, Shmuel “Muli” Ben Zvi, Ph.D. and Aharon Schwartz, Ph.D. ... Nominating Committee Chairman: Amos Bar Shalev; Membership: Amos Bar Shalev, Eliot Richard Forster, Ph.D. and Aharon Schwartz, Ph.D. ... The following table sets forth information with respect to compensation of our non-employee directors during fiscal year 2023. ... Fees Earned or Paid in Cash ($): 41,250; Option Award(s) ($): 38,660; Total ($): 79,910.